Ancillary Studies
Investigators are encouraged to propose and conduct ancillary studies related to the TARGET Trial. Ancillary studies refer to studies that are distinct from the main TARGET Trial, but propose questions and test hypotheses that are congruent with the goals and purposes of TARGET. Such studies may require tests or data that are not routinely obtained in the main TARGET Trial protocol, or may involve analyses of trial data in ways not planned in TARGET. Ancillary studies may involve some or all TARGET subjects and clinical sites, depending on the eligibility criteria of the study, sample size needed, or interest of the participating TARGET sites and investigators.
Ancillary studies will enhance the scientific value and productivity of TARGET, and help ensure the continued interest of the diverse group of investigators who are critical to the success of the trial. These studies provide an exceptional opportunity for investigators, either within or outside TARGET, to conduct additional projects leveraging the existing infrastructure of the ongoing trial. In general, ancillary studies will require additional funding from the NIH or other sources. For investigators interested in applying for NIH funding, the preferred mechanism for TARGET ancillary studies is the Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01), PAR-15-115. Discussions about the appropriateness of an individual project for this mechanism, and about other NIH funding mechanisms, can be pursued with NIAMS program officer, Dr. Jim Witter (witterj@mail.nih.gov).
Please refer to the documents below for submission guidelines and an application form to submit your ancillary proposal. Please email Kat Liao, kliao@partners.org, or Jon Giles, jtg2122@cumc.columbia.edu, with additional questions. Please submit your ancillary proposal to Alyssa Wohlfahrt at awohlfahrt@partners.org.
Ancillary studies will enhance the scientific value and productivity of TARGET, and help ensure the continued interest of the diverse group of investigators who are critical to the success of the trial. These studies provide an exceptional opportunity for investigators, either within or outside TARGET, to conduct additional projects leveraging the existing infrastructure of the ongoing trial. In general, ancillary studies will require additional funding from the NIH or other sources. For investigators interested in applying for NIH funding, the preferred mechanism for TARGET ancillary studies is the Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01), PAR-15-115. Discussions about the appropriateness of an individual project for this mechanism, and about other NIH funding mechanisms, can be pursued with NIAMS program officer, Dr. Jim Witter (witterj@mail.nih.gov).
Please refer to the documents below for submission guidelines and an application form to submit your ancillary proposal. Please email Kat Liao, kliao@partners.org, or Jon Giles, jtg2122@cumc.columbia.edu, with additional questions. Please submit your ancillary proposal to Alyssa Wohlfahrt at awohlfahrt@partners.org.
